Structural requirements of glycosaminoglycans for facilitating amyloid fibril formation of human serum amyloid A

Amyloid

Volumn 23, Issue 2, 2016, Pages 67-75

  Takase, Hiroka ^a   Tanaka, Masafumi ^a   Yamamoto, Aki ^a   Watanabe, Shiori ^a   Takahashi, Sanae ^a   Nadanaka, Satomi ^a   Kitagawa, Hiroshi ^a   Yamada, Toshiyuki ^b   Mukai, Takahiro ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

AA amyloidosis; amyloid fibril; glycosaminoglycan; serum amyloid A; sulfate group

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; DISACCHARIDE; GLUCOSAMINE; GLYCOSAMINOGLYCAN; HEPARIN; SULFATE; HEPARAN SULFATE; SERUM AMYLOID A; SOLUTION AND SOLUBILITY;

ARTICLE; ATOMIC FORCE MICROSCOPY; BETA SHEET; CARBOHYDRATE ANALYSIS; CIRCULAR DICHROISM; FLUORESCENCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECONDARY STRUCTURE; SULFATION; AMINO ACID SEQUENCE; CHEMISTRY; HUMAN; SOLUTION AND SOLUBILITY; SYNTHESIS;

AMINO ACID SEQUENCE; AMYLOID; CARBOHYDRATE SEQUENCE; HEPARIN; HEPARITIN SULFATE; HUMANS; SERUM AMYLOID A PROTEIN; SOLUTIONS; SULFURIC ACID ESTERS;

EID: 84964426444     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2016.1168292     Document Type: Article

References (40)

1. C.Gabay, I.Kushner Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–54.
2. F.C.De Beer, R.K.Mallya, E.A.Fagan, J.G.Lanham, G.R.Hughes, M.B.Pepys Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;2:231–4.
3. G.T.Westermark, M.Fandrich, P.Westermark AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 2015;10:321–44.
4. C.M.Uhlar, A.S.Whitehead Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265:501–23.
5. T.Yamada, J.J.Liepnieks, B.Kluve-Beckerman, M.D.Benson Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand J Immunol 1995;41:94–7.
6. T.Nakamura, S.Higashi, K.Tomoda, M.Tsukano, S.Baba, M.Shono Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford) 2006;45:43–9.
7. L.Obici, G.Merlini AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly 2012;142:w13580
8. G.T.Westermark, U.Engstrom, P.Westermark The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun 1992;182:27–33.
9. M.Egashira, H.Takase, I.Yamamoto, M.Tanaka, H.Saito Identification of regions responsible for heparin-induced amyloidogenesis of human serum amyloid A using its fragment peptides. Arch Biochem Biophys 2011;511:101–6.
10. J.Lu, Y.Yu, I.Zhu, Y.Cheng, P.D.Sun Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. Proc Natl Acad Sci USA 2014;111:5189–94.
11. H.Takase, M.Tanaka, S.Miyagawa, T.Yamada, T.Mukai Effect of amino acid variations in the central region of human serum amyloid A on the amyloidogenic properties. Biochem Biophys Res Commun 2014;444:92–7.
12. D.Real de Asua, R.Costa, J.M.Galvan, M.T.Filigheddu, D.Trujillo, J.Cadinanos Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 2014;6:369–77.
13. X.Zhang, J.P.Li Heparan sulfate proteoglycans in amyloidosis. Prog Mol Biol Transl Sci 2010;93:309–34.
14. X.Shi, J.Zaia Organ-specific heparan sulfate structural phenotypes. J Biol Chem 2009;284:11806–14.
15. Y.Inoue, K.Nagasawa Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol. Carbohydr Res 1976;46:87–95.
16. A.Ogamo, A.Metori, H.Uchiyama, K.Nagasawa Reactivity toward chemical sulfation of hydroxyl groups of heparin. Carbohydr Res 1989;193:165–72.
17. K.S.Dodgson, R.G.Price A note on the determination of the ester sulphate content of sulphated polysaccharides. Biochem J 1962;84:106–10.
18. A.Micsonai, F.Wien, L.Kernya, Y.H.Lee, Y.Goto, M.Refregiers, J.Kardos Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy. Proc Natl Acad Sci USA 2015;112:E3095–103.
19. Y.Yamauchi, N.Deguchi, C.Takagi, M.Tanaka, P.Dhanasekaran, M.Nakano, T.Handa,. Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study. Biochemistry 2008;47:6702–10.
20. J.D.Esko, K.Kimata, U.Lindahl Proteoglycans and Sulfated Glycosaminoglycans. In: A.Varki, R.D.Cummings, J.D.Esko, H.H.Freeze, P.Stanley, C.R.Bertozzi,., eds. Essentials of glycobiology. 2nd ed. Cold Spring Harbor Laboratory Press (NY) 2009.
21. M.Ueno, S.Yamada, M.Zako, M.Bernfield, K.Sugahara Structural characterization of heparan sulfate and chondroitin sulfate of syndecan-1 purified from normal murine mammary gland epithelial cells. Common phosphorylation of xylose and differential sulfation of galactose in the protein linkage region tetrasaccharide sequence. J Biol Chem 2001;276:29134–40.
22. J.T.Gallagher Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001;108:357–61.
23. J.P.Li, M.L.Galvis, F.Gong, X.Zhang, E.Zcharia, S.Metzger, I.Vlodavsky,. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci U S A 2005;102:6473–7.
24. E.Bazar, R.Jelinek Divergent heparin-induced fibrillation pathways of a prion amyloidogenic determinant. Chembiochem 2010;11:1997–2002.
25. M.Stefani Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits. Prog Neurobiol 2012;99:226–45.
26. G.M.Castillo, W.Lukito, T.N.Wight, A.D.Snow The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 1999;72:1681–7.
27. R.Kisilevsky, L.J.Lemieux, P.E.Fraser, X.Kong, P.G.Hultin, W.A.Szarek Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995;1:143–8.
28. J.J.Aguilera, F.Zhang, J.M.Beaudet, R.J.Linhardt, W.Colon Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A. Biochimie 2014;104:70–80.
29. M.L.Hegde, K.S.Rao DNA induces folding in alpha-synuclein: understanding the mechanism using chaperone property of osmolytes. Arch Biochem Biophys 2007;464:57–69.
30. F.Noborn, P.O'Callaghan, E.Hermansson, X.Zhang, J.B.Ancsin, A.M.Damas, I.Dacklin,. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc Natl Acad Sci USA 2011;108:5584–9.
31. N.Motamedi-Shad, E.Monsellier, F.Chiti Amyloid formation by the model protein muscle acylphosphatase is accelerated by heparin and heparan sulphate through a scaffolding-based mechanism. J Biochem 2009;146:805–14.
32. J.Y.Suk, F.Zhang, W.E.Balch, R.J.Linhardt, J.W.Kelly Heparin accelerates gelsolin amyloidogenesis. Biochemistry 2006;45:2234–42.
33. A.Walker, J.T.Gallagher Structural domains of heparan sulphate for specific recognition of the C-terminal heparin-binding domain of human plasma fibronectin (HEPII). Biochem J 1996;317:871–7.
34. L.M.Dember, P.N.Hawkins, B.P.Hazenberg, P.D.Gorevic, G.Merlini, I.Butrimiene, A.Livneh,. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349–60.
35. N.S.Gandhi, R.L.Mancera Heparin/heparan sulphate-based drugs. Drug Disco Today 2010;15:1058–69.
36. J.S.Wall, T.Richey, A.Stuckey, R.Donnell, S.Macy, E.B.Martin, A.Williams,. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci USA 2011;108:E586–94.
37. G.Sugumaran, R.Elliott-Bryant, N.Phung, O.Vitseva, B.Kuberan, M.Lech Characterization of splenic glycosaminoglycans accumulated in vivo in experimentally induced amyloid-susceptible and amyloid-resistant mice. Scand J Immunol 2004;60:574–83.
38. E.Feyzi, T.Saldeen, E.Larsson, U.Lindahl, M.Salmivirta Age-dependent modulation of heparan sulfate structure and function. J Biol Chem 1998;273:13395–8.
39. M.B.Huynh, C.Morin, G.Carpentier, S.Garcia-Filipe, S.Talhas-Perret, V.Barbier-Chassefiere, T.van Kuppevell,. Age-related changes in rat myocardium involve altered capacities of glycosaminoglycans to potentiate growth factor functions and heparan sulfate-altered sulfation. J Biol Chem 2012;287:11363–73.
40. Y.Okuda, T.Yamada, M.Matsuura, K.Takasugi, M.Goto Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid 2011;18:108–11.